Bausch + Lomb (BLCO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.34
- Estimate
- $0.22
- Surprise
- +54.7%
- Revenue (period 2026-09-30)
- $1.38B
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Bausch + Lomb (BLCO) beat the $0.22 estimate with adjusted EPS of $0.34 — a large 54.7% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BLCO Hold at 5.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +54.7% surprise compares with a +23.3% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: Vision Care segment (57.0%)
- Concentration risk — Supplier: single source or limited number of sources
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.00
- Stop
- $19.53
Risk check: RSI 76 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
BLCO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $7.29B
- P/E (fwd)
- 18.3
- 52-week range
- $14.44–$20.43
- Off 52-week high
- -2.8%
- RSI (14)
- 76
- Volume vs avg
- 0.33×
- Score today
- 5.6/10